-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3122 Impact of Pre-Transplant Diffusion Lung Capacity for Nitric Oxide (DLNO) and of Dlno/Pre-Transplant Diffusion Lung Capacity for Carbon Monoxide (DLNO/DLCO) Ratio on Pulmonary Outcomes in Adults Receiving Allogeneic Stem Cell Transplantation for Haematological Diseases

Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities
Program: Oral and Poster Abstracts
Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Poster II
Sunday, December 6, 2015, 6:00 PM-8:00 PM
Hall A, Level 2 (Orange County Convention Center)

Amandine Le Bourgeois1*, Florent Malard1,2,3*, Patrice Chevallier, MD, PhD4*, Thierry Guillaume, MD, PhD4*, Jacques Delaunay, MD4*, Pierre Peterlin, MD4*, Patricia Lemarchand, MD, PhD5*, Patrick Germaud, MD5*, Mohamad Mohty, MD, PhD6,7, Philippe Moreau8* and Arnaud Chambellan, MD5*

1Department of Hematology, Nantes University Hospital, Hôtel Dieu, Nantes, France
2UMR 1064-Center for Research in Transplantation and Immunology, INSERM, Nantes, France
3UMRs 938, Paris, France and Université Pierre et Marie Curie, INSERM, Nantes, France
4Department of Hematology, Nantes University Hospital, Nantes, France
5INSERM, UMR1087, l’institut du thorax, Nantes, France
6Hematology Department, Saint-Antoine Hospital, AP-HP, Universite Pierre et Marie Curie, Paris, France
7Hospital Saint-Antoine, Paris University UPMC, INSERM U938, Paris, France
8Nantes University Hospital, Hôtel‐Dieu, Nantes, France

Background: Pre-transplant pulmonary function testing (PFT) is required in all patients eligible for allogeneic stem cell transplantation (allo-SCT). Diffusion lung capacity for carbon monoxide (DLCO) is the main parameter taken into account but the overall impact of this factor is debated. Diffusion lung capacity for nitric oxide (DLNO) may be of higher interest to predict pulmonary complications, because radiotherapy and chemotherapy used to treat patients with haematological diseases affect mostly the alveolar-capillary membrane, which destruction is more appreciate by DLNO than DLCO measure. Also, DLNO/DLCO ratio represents a new index of gas exchange and an alternative way of investigating the alveolar membrane and the blood reacting with the gas.

Methods: We considered all patients who received an allo-SCT for hematological malignancies between March 2012 and January 2014 in our department and for whom a pre-transplant PFT, including DLCO and DLNO measures, was validated. Factors influencing pre-transplant DLCO, DLNO and DLNO/DLCO ratio were analyzed as well as impact of those 3 diffusion lung parameters on general outcomes and pulmonary complications (severe pulmonary complications (SPC) defined as any pulmonary complication responsible for hospitalization, pulmonary related mortality (PRM), acute respiratory distress syndrome (ARDS).

Results: We included 103 patients (male: n=68, median age at transplant: 58 years) in this study. Majority of them had a myeloid disease (n=67), and were in complete (n=56) or partial (n=23) remission at transplant. Type of donor was: matched related donor (N=35), haploidentical related donor (n=5), matched unrelated donor (n=43), mismatched unrelated donor (n=9) and umbilical cord blood (n=10). First stem cell source used was peripheral blood stem cell (n=83). Eight five percent of patient received a reduced intensity regimen. With a median follow up of 21.5 months (range: 3.8-34.7), 2 year cumulative incidence of overall survival, Disease free survival, relapse incidence, non-relapse mortality, SPC, ARDS and PRM were respectively 65.4% ( 55.2-73.6), 52.5% (42.7-62.2), 31.8% (22.3-41.7), 15.8% (9.4-23.5), 25.4% (17-34), 7.8% (4-14), and 4.9% (1.8-10.4). Normal DLCO and DLNO percentages of predicted normal value (>80%) were documented in 48 and 44 patients, respectively but median percentages for the all cohort were under the normal at transplant: DLCO: 78.9%, DLNO: 78.1%. Median DLNO/DLCO ratio was 5.3 (range: 2.7-8.6). Regarding factors influencing pre-transplant PFT results, DLCO was significantly decreased in patients with respiratory history (72.3% versus 81.5%, p=0.001), in patients having received therapeutic with cardiac or pulmonary toxicities (74.2% versus 80.6%, p=0.02) and in patients over 58 years (81.0% versus 75.4%, p=0.05). Similarly, DLNO was significantly decreased in patients with respiratory history (74.3% versus 80.9%, p=0.03) and in patients’ smokers or with history of smoking (75.3% versus 81.8%, p=0.03). Finally, patients’ age was the only parameter with a significant impact on DLNO/DLCO (5.5 in patients >58 years versus 5.2 in patients ≤58years, p=0.04). In univariate analysis, a DLNO value <60% of predicted normal value was associated with higher incidences of SPC (p=0.02) and acute respiratory distress syndrome (ARDS) (p<0.005). When considering DLCO and DLNO as continuous variables, lower percentage were associated with higher risk of SPC for both parameters (p=0.048 and p=0.026, respectively). Also, lower DLNO/DLCO ratio (considered as a continuous variable) was associated with higher PRM (p=0.04). In multivariate analysis, there was a trend for an association between lower value of pre-transplant DLNO (<60%) and higher risk of ARDS (HR: 3.34, 95%CI: 0.99-11.2, p=0.05) and of SPC (HR: 2.5, 95%CI: 0.93-7.12, p=0.06).

Conclusion: DLNO and DLNO/DLCO ratio may be more appropriate to predict pulmonary complications than DLCO alone after allo-SCT. These results have to be confirmed prospectively.

Disclosures: Mohty: Janssen: Honoraria ; Celgene: Honoraria . Moreau: Takeda: Other: Adboard ; Amgen: Other: Adboard ; Novartis: Other: Adboard ; Celgene: Honoraria , Other: Adboard ; Janssen: Other: Adboard .

*signifies non-member of ASH